Head-to-Head drug trial aims to find better treatment for rare autoimmune lung disease
NCT ID NCT07406932
Summary
This study aims to find out which of two types of drugs works better for people with a rare autoimmune condition that causes lung scarring. It will compare JAK inhibitors (like tofacitinib) against calcineurin inhibitors (like tacrolimus), both given with standard steroids, in 80 adults who haven't had treatment before. The main goal is to see which group has better 12-month survival and lung function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE (ILD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.